Holen Sie sich die Stockscreener-App
2.05
4.21%
-0.09
Handel nachbörslich:
2.05
Compugen Ltd Aktie (CGEN) Neueste Nachrichten
BillionToOne Stock at $89: Why a New $19.1 Million Position Could Matter Now - AOL.com
3 Reasons Exelixis Stock Could Deliver Market‑Beating Returns Over the Next Decade - AOL.com
Compugen Ltd (CGEN) Q4 2025 Earnings Call Highlights: Strong Rev - GuruFocus
Why Tempus AI Stock Is Up Today — And What to Watch Before Next Week’s Earnings - AOL.com
Cumberland (CPIX) Q4 2025 Earnings Call Transcript - AOL.com
Compugen (CGEN) Quarterly Loss Near US$7 Million Tests Bullish Profitability Narrative - simplywall.st
Compugen (CGEN) Q4 2025 Earnings Call Transcript - The Globe and Mail
From Sizable Stake to Zero: The Likely Reason Why Agios Shares Lost a $94 Million Backer - AOL.com
Investment Advisor Bets Big on CMPX Stock, Adds 2.5 Million Shares, According to Latest SEC Filing - AOL.com
Compugen earnings beat by $0.68, revenue topped estimates - Investing.com South Africa
Chegg Earnings: Big Quarter Sends Shares Higher - AOL.com
Compugen: Non-Dilutive Funding For Rilvegostomig Obtained And GS-0321 Advancement (CGEN) - Seeking Alpha
Compugen Ltd. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
Compugen Q4 2025 Earnings Call Transcript - MarketBeat
Compugen Ltd. Q4 2025 Earnings Call Summary - Yahoo Finance
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
What Smart Money Loves About Lilly - AOL.com
Viridian Therapeutics Stock Up 75%, but One Fund Just Sold Off Its $69 Million Stake - AOL.com
Earnings call transcript: Compugen Q4 2025 sees earnings beat, stock surges - Investing.com Nigeria
CGEN: 2025 saw a cash runway extension, profitability, and global clinical trial progress - TradingView
Compugen Ltd reports results for the quarter ended December 31Earnings Summary - TradingView
CGEN: 2025 saw strong revenue growth, a return to profitability, and extended cash runway into 2029 - TradingView
Compugen: Overview of Fourth Quarter Financial Results - Bitget
Compugen (CGEN) Beats Q4 Earnings and Revenue Estimates - Yahoo Finance
Compugen Extends Cash Runway to 2029 and Swings to Profit on AstraZeneca Deal and Clinical Progress - TipRanks
Partnership payments lift Compugen (NASDAQ: CGEN) to 2025 profit - Stock Titan
COMPUGEN ($CGEN) Releases Q4 2025 Earnings - Quiver Quantitative
Compugen stock jumps 5% on fourth quarter earnings beat - Investing.com
Compugen: Q4 Earnings Snapshot - marketscreener.com
Compugen : Corporate Presentation - marketscreener.com
Earnings Breakdown: Compugen Q4 - Benzinga
CGEN: Profitability achieved in 2025, driven by AstraZeneca deal and robust clinical progress - TradingView
Compugen (Nasdaq: CGEN) swings to 2025 profit, extends cash runway to 2029 - Stock Titan
Compugen Reports Fourth Quarter and Full Year 2025 Results - Yahoo Finance
Biotech Fund Dumps $84 Million of Nuvalent With Stock Up 29% - AOL.com
Uncovering Potential: Compugen's Earnings Preview - Benzinga
Compugen Ltd expected to post earnings of 5 cents a shareEarnings Preview - TradingView
This Fund Just Disclosed a New $55 Million Bet on Centessa Amid 53% Stock Rally and CEO Transition - AOL.com
Compugen Ltd (CGEN) Q4 2025: Everything You Need To Know Ahead O - GuruFocus
MSN Money - MSN
Compugen CEO Highlights COM701 Ovarian Cancer MAIA Trial, AstraZeneca and Gilead Updates at Oppenheimer Conf - Defense World
Biotech Fund Dumps 1.85 Million Centessa Shares as Stock Jumps Over 50% - AOL.com
Compugen at Oppenheimer Conference: Strategic Insights on Partnerships - Investing.com India
Apogee Therapeutics Stock Up 100% as Fund Lifts Stake to $28 Million - AOL.com
This Fund Bet $20 Million on RAPT Therapeutics as Stock Surges 500% This Past Year and Buyout Offer Emerges - AOL.com
Here's Why Grail Stock Bounced Back 16% Today - AOL.com
Is Immunovant Stock a Buy After Roivant Sciences Increased Its Stake by $350 Million? - AOL.com
Is Compass Stock a Buy After Kanen Added 1.6 Million Shares to Its Position? - AOL.com
Analyzing Sana Biotechnology (NASDAQ:SANA) & Compugen (NASDAQ:CGEN) - Defense World
Exelixis: The Cash‑Generating Biotech That I Think Deserves a Closer Look in 2026 - AOL.com
Agios Stock Down 16% in a Year as Fund Cuts Stake by $5.6 Million After 50% November Crash - AOL.com
Xenon Stock at $42: What to Know of a $75 Million Trim Ahead of March Phase 3 Data - AOL.com
Cancer immunotherapy firm Compugen to stream talks from two investor conferences - Stock Titan
Compugen to Participate in Upcoming Investor Conferences - Yahoo Finance
Cogent Biosciences Stock Soars 346% in a Year, but One Fund Just Sold Off $4.5 Million - AOL.com
Why Did Compass Pathways Stock Rocket Higher Today? - AOL.com
Compugen to Release Fourth Quarter and Full Year 2025 Results on Monday, March 2, 2026 - Yahoo Finance
Should You Buy Compugen Ltd (CGEN) Today? Analysis, Price Targets, and 2026 Outlook. - Intellectia AI
Buyout Rumor: Does SEALSQ Corp outperform in volatile marketsMarket Risk Report & Expert Verified Movement Alerts - baoquankhu1.vn
Gains Recap: Does Auddia Inc Equity Warrant have pricing powerGold Moves & Expert Curated Trade Setups - baoquankhu1.vn
Gains Recap: What is the cash position of Compugen LtdJuly 2025 Catalysts & Weekly Stock Performance Updates - baoquankhu1.vn
Does Compugen Ltd. meet Warren Buffett’s criteriaWeekly Trade Summary & Long Hold Capital Preservation Tips - mfd.ru
What’s the analyst consensus on Compugen Ltd.2025 Stock Rankings & Safe Entry Point Identification - mfd.ru
VistaGen (VTGN) Q3 2026 Earnings Call Transcript - AOL.com
Compugen announces the appointment of Michele Holcomb, Ph.D., to its board of directors - marketscreener.com
Compugen Adds Veteran Healthcare Strategist Michele Holcomb to Board of Directors - TipRanks
[6-K] COMPUGEN LTD Current Report (Foreign Issuer) | CGEN SEC FilingForm 6-K - Stock Titan
3.69%
0.68%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):